Amazingly, Checkmate 649 and Orient 16 clinical trials had demonstrated that PD-1 (nivolumab and sintilimab) inhibitors combined with chemotherapy might become the standard of care as first-line therapy for patients with advanced GC soon, which were both reported in 2021 [8, 22]. This evidence concerns the gene PDCD1 and gastric cancer.